Connect with us

Health

Amphetamines Stimulants Double the Psychosis Risk for Young People Suffering from ADHD

mm

Published

on

It has been found in a study that young adults who suffer from attention deficit-hyperactivity disorder, ADHD may develop a high risk of psychosis if they rely on amphetamines stimulants such as Adderall to treat the disorder. Those who receive other types of stimulants such as Ritalin are less prone to psychosis risk.

After analyzing the insurance claim databases (between 2004 to 2015) of over 2 Lakhs young adults ranging from 13 to 25 with ADHD, it was observed that one out of every 660 young people suffered from psychosis even after the first few months of starting a stimulant. And the risk factor for the side effect of Amphetamines stimulants was double than that of taking methylphenidate.

Dr. Lauren Moran, the assistant professor at Harvard Medical School, carried out the observations on young people with ADHD taking amphetamines such as Adderall. People who face the problem of ADHD experience problems such as inattention, hyperactivity, and severe impulsivity. Many people who are aware of the side-effects of stimulants go for other alternatives to reduce ADHD problem. In order to help them find ways on how to focus on daily routine, people also go for natural alternatives to Adderall to treat symptoms of ADHD.

The U.S Food and Drug Administration issued the guidelines to manufacturers to mention the warning of using stimulants on drug labels. But still, there is an increase in the number of young people taking stimulants such as amphetamine as the treatment for ADHD. Dr. Moran said that the effect is less severe for first timers if they go for stimulants after taking a prescription from their doctors.

Michelle has been a part of the journey ever since Bigtime Daily started. As a strong learner and passionate writer, she contributes her editing skills for the news agency. She also jots down intellectual pieces from categories such as science and health.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

BioLongevity Labs: How Two Biohackers Are Making Longevity Safe for the Mainstream

mm

Published

on

Humans have been looking for ways to extend their lifespan for hundreds of years. Medicine has made impressive strides, but for many, the effects of aging are still painfully real.

Through BioLongevity Labs, biohackers and entrepreneurs Jay Campbell and Josh Felber aim to introduce ordinary people to potentially life-changing compounds called peptides. Campbell and Felber come from very different backgrounds.

Campbell is a five-time international bestselling author and globally recognized leader in the health-optimization space. Felber is a serial entrepreneur who excels at scaling businesses.

For both men, BioLongevity Labs is more than just a business venture — it’s about helping everyday people discover something that just might prolong and improve their lives.

“Your body inevitably changes as the years pile on,” says Campbell. “Your energy drops, and wrinkles start showing up uninvited. Peptides can change everything.”

Many people have probably heard the term “peptide” in passing. Some may know they’re associated with longevity. Most people just don’t have a strong grasp of how they work.

A peptide is a short chain of amino acids, which are the building blocks of proteins. Essentially, peptides are like shorter, simpler proteins. That might sound unremarkable, but the real magic of peptides lies in how they work.

They function as signaling or “messenger” molecules telling the body to perform specific functions. Many peptides function similarly to hormones. A relevant example is GLP-1 (glucagon-like peptide-1) receptor agonists. This class of medications includes semaglutide and tirzepatide, two wildly popular weight-loss drugs.

“These peptides aren’t just another biohacking fad,” Campbell explains. “They enhance insulin secretion and suppress glucagon release to balance blood sugar levels and promote sustainable weight loss”. But what sets GLP-1 receptor agonists apart is their ability to regulate hunger.

Through the reduction of appetite and increased feelings of fullness, it is far easier for dieters to stick to a calorie deficit.” Although GLP-1 receptor agonists are widely prescribed, most peptides aren’t.

Campbell asserts, because many peptides have the potential to cure illnesses by treating the fundamental root cause, they go against America’s “sick care” model of healthcare. They potentially threaten drug companies and their bottom line.

“Peptides are simultaneously a dream come true for mankind and the worst possible nightmare for the pharmaceutical industry,” says Campbell. “It’s not a conspiracy theory. It’s pure economics and psychology in action. People will do whatever it takes to make as much money as possible in a free-market society, even if it means suppressing a superior solution.”

Patients probably aren’t going to be introduced to peptides through the healthcare system. Many discover them on their own. But for the many people who don’t have a solid understanding of how they work molecularly or even what dose to take, there is a risk. That’s precisely what BioLongevity Labs’ co-founders are attempting to address.

Jay Campbell has dedicated his life to educating people about therapeutic peptides and optimized hormones, and along with his partner Josh Felber, they’ve created a company offering filler-free, third-party tested peptides and bioregulators.

Campbell and Felber stress the fact that BioLongevity Labs isn’t meant to be a replacement for traditional medical care. Instead, its products bridge the gap between clinical and extra-clinical care. There’s no magic pill or single solution to solve the problem of aging.

But thanks to the development of specialized peptides, bioregulators, and small molecules, we’re closer than we’ve ever been before.

Continue Reading

Trending